0001096906-24-000493.txt : 20240318 0001096906-24-000493.hdr.sgml : 20240318 20240318180048 ACCESSION NUMBER: 0001096906-24-000493 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240314 FILED AS OF DATE: 20240318 DATE AS OF CHANGE: 20240318 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hansard Adam CENTRAL INDEX KEY: 0001805556 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38898 FILM NUMBER: 24760400 MAIL ADDRESS: STREET 1: C/O APPLIED THERAPEUTICS, INC. STREET 2: 545 5TH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Applied Therapeutics, Inc. CENTRAL INDEX KEY: 0001697532 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 545 FIFTH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-220-9226 MAIL ADDRESS: STREET 1: 545 FIFTH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: Applied Therapeutics Inc. DATE OF NAME CHANGE: 20170208 4 1 form4.xml PRIMARY DOCUMENT X0508 4 2024-03-14 0 0001697532 Applied Therapeutics, Inc. APLT 0001805556 Hansard Adam C/O APPLIED THERAPEUTICS, INC. 545 FIFTH AVENUE, SUITE 1400 NEW YORK NY 10017 0 1 0 0 Chief Commercial Officer 0 Common Stock 2024-03-14 4 S 0 48871.0000 5.3900 D 732919.0000 D The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of compensatory Restricted Stock Units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person. Weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $5.37 to $5.795, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. /s/ Shoshana Shendelman, Attorney-in-Fact 2024-03-18